Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: ESMO Open Volume 7, Issue 2, April 2022, 100447
Gespeichert in:
| Veröffentlicht in: | ESMO open 2022-07, Vol.7 (4) |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | |
| container_title | ESMO open |
| container_volume | 7 |
| creator | Ochsenreither, S. Fiedler, W.M. Del Conte, G. Macchini, M. Matos, I. Habel, B. Ahrens-Fath, I. Raspagliesi, F. Lorusso, D. Keilholz, U. Rolling, C. Kebenko, M. Klinghammer, K.F. Saavedra, O. Baumeister, H. Zurlo, A. Garralda, A. |
| description | |
| doi_str_mv | 10.1016/j.esmoop.2022.100549 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9293584</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_9293584</sourcerecordid><originalsourceid>FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_92935843</originalsourceid><addsrcrecordid>eNqlkEtOwzAQhi0kRCvoDVjMAUhx0vSRDVJV9cECIUFYR07jNFPFduRHoV31GHA0tj0JbkFCrFmN5p9vfv0zhFyHtBvScHC77nIjlGq6EY0iL9F-nJyRdkT7STCkUdIiHWPWlNJwGHtxcEFavf4oDkc0bpPPqdbMOgFWwWH__sxKbrfAZAGN5jUKlEz7fmlxg36guXG1NaBKsBWH-ThNH8FYV2xvgEFTMcPhPv9WYKlEjhLl6sQyaTFIx8HDyyQ8NbnyzJxZbJR1OydYDq9oq194Op89QaqE23ngDY8ASmj8Bpc-wwnWvNQ-nfIhjaqxAH-L0uaw_7gi5yWrDe_81EtyN5umk0XQuFzwYuk9NKuzRntjvc0Uw-zvRGKVrdQmS6Lk-K_evw2-AEVUkzs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: ESMO Open Volume 7, Issue 2, April 2022, 100447</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Ochsenreither, S. ; Fiedler, W.M. ; Del Conte, G. ; Macchini, M. ; Matos, I. ; Habel, B. ; Ahrens-Fath, I. ; Raspagliesi, F. ; Lorusso, D. ; Keilholz, U. ; Rolling, C. ; Kebenko, M. ; Klinghammer, K.F. ; Saavedra, O. ; Baumeister, H. ; Zurlo, A. ; Garralda, A.</creator><creatorcontrib>Ochsenreither, S. ; Fiedler, W.M. ; Del Conte, G. ; Macchini, M. ; Matos, I. ; Habel, B. ; Ahrens-Fath, I. ; Raspagliesi, F. ; Lorusso, D. ; Keilholz, U. ; Rolling, C. ; Kebenko, M. ; Klinghammer, K.F. ; Saavedra, O. ; Baumeister, H. ; Zurlo, A. ; Garralda, A.</creatorcontrib><identifier>EISSN: 2059-7029</identifier><identifier>DOI: 10.1016/j.esmoop.2022.100549</identifier><identifier>PMID: 35841804</identifier><language>eng</language><publisher>Elsevier</publisher><subject>Erratum</subject><ispartof>ESMO open, 2022-07, Vol.7 (4)</ispartof><rights>2022 The Author(s) 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293584/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293584/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Ochsenreither, S.</creatorcontrib><creatorcontrib>Fiedler, W.M.</creatorcontrib><creatorcontrib>Del Conte, G.</creatorcontrib><creatorcontrib>Macchini, M.</creatorcontrib><creatorcontrib>Matos, I.</creatorcontrib><creatorcontrib>Habel, B.</creatorcontrib><creatorcontrib>Ahrens-Fath, I.</creatorcontrib><creatorcontrib>Raspagliesi, F.</creatorcontrib><creatorcontrib>Lorusso, D.</creatorcontrib><creatorcontrib>Keilholz, U.</creatorcontrib><creatorcontrib>Rolling, C.</creatorcontrib><creatorcontrib>Kebenko, M.</creatorcontrib><creatorcontrib>Klinghammer, K.F.</creatorcontrib><creatorcontrib>Saavedra, O.</creatorcontrib><creatorcontrib>Baumeister, H.</creatorcontrib><creatorcontrib>Zurlo, A.</creatorcontrib><creatorcontrib>Garralda, A.</creatorcontrib><title>Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: ESMO Open Volume 7, Issue 2, April 2022, 100447</title><title>ESMO open</title><subject>Erratum</subject><issn>2059-7029</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqlkEtOwzAQhi0kRCvoDVjMAUhx0vSRDVJV9cECIUFYR07jNFPFduRHoV31GHA0tj0JbkFCrFmN5p9vfv0zhFyHtBvScHC77nIjlGq6EY0iL9F-nJyRdkT7STCkUdIiHWPWlNJwGHtxcEFavf4oDkc0bpPPqdbMOgFWwWH__sxKbrfAZAGN5jUKlEz7fmlxg36guXG1NaBKsBWH-ThNH8FYV2xvgEFTMcPhPv9WYKlEjhLl6sQyaTFIx8HDyyQ8NbnyzJxZbJR1OydYDq9oq194Op89QaqE23ngDY8ASmj8Bpc-wwnWvNQ-nfIhjaqxAH-L0uaw_7gi5yWrDe_81EtyN5umk0XQuFzwYuk9NKuzRntjvc0Uw-zvRGKVrdQmS6Lk-K_evw2-AEVUkzs</recordid><startdate>20220713</startdate><enddate>20220713</enddate><creator>Ochsenreither, S.</creator><creator>Fiedler, W.M.</creator><creator>Del Conte, G.</creator><creator>Macchini, M.</creator><creator>Matos, I.</creator><creator>Habel, B.</creator><creator>Ahrens-Fath, I.</creator><creator>Raspagliesi, F.</creator><creator>Lorusso, D.</creator><creator>Keilholz, U.</creator><creator>Rolling, C.</creator><creator>Kebenko, M.</creator><creator>Klinghammer, K.F.</creator><creator>Saavedra, O.</creator><creator>Baumeister, H.</creator><creator>Zurlo, A.</creator><creator>Garralda, A.</creator><general>Elsevier</general><scope>5PM</scope></search><sort><creationdate>20220713</creationdate><title>Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’</title><author>Ochsenreither, S. ; Fiedler, W.M. ; Del Conte, G. ; Macchini, M. ; Matos, I. ; Habel, B. ; Ahrens-Fath, I. ; Raspagliesi, F. ; Lorusso, D. ; Keilholz, U. ; Rolling, C. ; Kebenko, M. ; Klinghammer, K.F. ; Saavedra, O. ; Baumeister, H. ; Zurlo, A. ; Garralda, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_92935843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Erratum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ochsenreither, S.</creatorcontrib><creatorcontrib>Fiedler, W.M.</creatorcontrib><creatorcontrib>Del Conte, G.</creatorcontrib><creatorcontrib>Macchini, M.</creatorcontrib><creatorcontrib>Matos, I.</creatorcontrib><creatorcontrib>Habel, B.</creatorcontrib><creatorcontrib>Ahrens-Fath, I.</creatorcontrib><creatorcontrib>Raspagliesi, F.</creatorcontrib><creatorcontrib>Lorusso, D.</creatorcontrib><creatorcontrib>Keilholz, U.</creatorcontrib><creatorcontrib>Rolling, C.</creatorcontrib><creatorcontrib>Kebenko, M.</creatorcontrib><creatorcontrib>Klinghammer, K.F.</creatorcontrib><creatorcontrib>Saavedra, O.</creatorcontrib><creatorcontrib>Baumeister, H.</creatorcontrib><creatorcontrib>Zurlo, A.</creatorcontrib><creatorcontrib>Garralda, A.</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>ESMO open</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ochsenreither, S.</au><au>Fiedler, W.M.</au><au>Del Conte, G.</au><au>Macchini, M.</au><au>Matos, I.</au><au>Habel, B.</au><au>Ahrens-Fath, I.</au><au>Raspagliesi, F.</au><au>Lorusso, D.</au><au>Keilholz, U.</au><au>Rolling, C.</au><au>Kebenko, M.</au><au>Klinghammer, K.F.</au><au>Saavedra, O.</au><au>Baumeister, H.</au><au>Zurlo, A.</au><au>Garralda, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: ESMO Open Volume 7, Issue 2, April 2022, 100447</atitle><jtitle>ESMO open</jtitle><date>2022-07-13</date><risdate>2022</risdate><volume>7</volume><issue>4</issue><eissn>2059-7029</eissn><pub>Elsevier</pub><pmid>35841804</pmid><doi>10.1016/j.esmoop.2022.100549</doi></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 2059-7029 |
| ispartof | ESMO open, 2022-07, Vol.7 (4) |
| issn | 2059-7029 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9293584 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Erratum |
| title | Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: ESMO Open Volume 7, Issue 2, April 2022, 100447 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T05%3A26%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Erratum%20to%20%E2%80%98Safety%20and%20preliminary%20activity%20results%20of%20the%20GATTO%20study,%20a%20phase%20Ib%20study%20combining%20the%20anti-TA-MUC1%20antibody%20Gatipotuzumab%20with%20the%20anti-EGFR%20Tomuzotuximab%20in%20patients%20with%20refractory%20solid%20tumors%E2%80%99:%20ESMO%20Open%20Volume%207,%20Issue%202,%20April%202022,%20100447&rft.jtitle=ESMO%20open&rft.au=Ochsenreither,%20S.&rft.date=2022-07-13&rft.volume=7&rft.issue=4&rft.eissn=2059-7029&rft_id=info:doi/10.1016/j.esmoop.2022.100549&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_9293584%3C/pubmedcentral%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/35841804&rfr_iscdi=true |